Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Adds Flagship To Its Venture Fund Network

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck contributes to Flagship’s latest fund, both sides promise to share ideas and expertise, but Merck gets no special rights to companies or products in Flagship’s portfolio.

You may also be interested in...



Merck’s Iain Dukes On New BD Culture: Regional Hubs And Sourcing Innovation

Since Dukes arrived six months ago as head of Merck Research Labs’ licensing and external affairs, Merck has consolidated and restructured its scattered business development functions, rolled out its regional BD hubs, and rationalized the distinction between equity investments and venture fund investments

Amgen, Novartis Are Investors In Atlas Venture’s Ninth Fund

Atlas pledges to explore areas of mutual interest to the firm and its new corporate limited partners, but the drug firms won’t receive exclusive rights to anything in the new fund’s portfolio.

Lilly And Canadian VCs To Fund TVM Life Sciences VII To Develop Single-Asset Companies

Lilly and Canadian VCs back a new TVM Life Sciences fund that will invest in a network of single-asset companies in Quebec.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel